Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH

Benzinga Newsdesk www.benzinga.com Positive 88.7%

Neg 0% Neu 0% Pos 88.7%

Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies
- This latest approval marks Guardant’s 31st CDx approval

Comments

No comments yet. Be the first!